Opko Health Q2 top line up 33% on surge in reference lab unit

• OPKO Health (NASDAQ:OPK) Q2 results:
• Revenues: $301.2M (+33.0%); reference lab services: $251.0M (+40.6%); product sales: $29.3M (+2.1%).
• Net income: $33.7M (+156.4%); EPS: $0.05 (+150.0%).
• BioReference Labs unit processed ~2.2M COVID-19 molecular tests during the quarter.
• Shares down 3% after-hours.
• OPKO Health EPS beats by $0.13, beats on revenue